pre-menstrual-syndrome-treatment-market

Pre-Menstrual Syndrome Treatment Market By Drug (Analgesics (Pain Killers), Oral Contraceptive Pills (OCPs), Gonadotropin-Releasing Hormone (GnRH), Antidepressants, Ovarian Suppressors, Diuretics, Benzodiazepines) - Growth, Future Prospects And Competitive Analysis, 2024 - 2032

20 Mar 2017 Format PDF icon PPT icon XLS icon Request Sample

Pre-menstrual syndrome (PMS) is a medical condition in women that occurs during childbearing age. It is estimated that more than one in three women suffer from PMS; and one in every twenty women demonstrate life disturbing symptoms. Pre-menstrual dysphoric disorder (PMDD) is a further severe form of PMS and demonstrates more severe symptoms of PMS, often interfering with social activities, work and emotional balance. PMDD occurs in 3% to 5% of menstruating women. Though the exact cause of PMS is unknown, it is reported that fluctuating levels of hormones (estrogen and progesterone) are related to PMS symptoms. The treatment regimen of PMS is temporary i.e. administered only for symptom management before the onset of menstrual cycle. Education, nutrition, exercise and medication together form the complete layout of PMS treatment module.

The report titled “Pre-menstrual Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023–2030” offers strategic insights into the overall pre-menstrual syndrome treatment market along with the market size and estimates for the duration 2020 to 2030. The said research study covers in-depth analysis of multiple market segments based on type of drugs and different geographies. The drug types studied for analyzing the overall global pre-menstrual syndrome treatment market are majorly segmented into analgesics (pain killers), oral contraceptive pills (OCPs), gonadotropin-releasing hormone (GnRH), antidepressants, ovarian suppressors, diuretics and benzodiazepines.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global pre-menstrual syndrome treatment market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global pre-menstrual syndrome treatment market. This report concludes with company profiles section that highlights major information about the key players engaged in global pre-menstrual syndrome treatment market. In-depth competitive environment analysis and historical (2020) market size data are also provided in the report.

Common painkillers available for treating PMS are NSAIDS and paracetamol. This segment is majorly dominated by over-the-counter drugs that are cheap and easily available in the market. For depression and anxiety, particularly in patients with PMDD, drugs such as SSRIs (commonly fluoxetine and sertraline) are commonly prescribed. GnRH i.e. synthetic hormones are prescribed to initiate temporary menopause in patients with severe PMS. It is observed that the demand for hormone-based PMS treatments is on a perpetual rise and will continue through the forecast period.

At present, North America and Europe dominate the premenstrual syndrome treatment market due to increase in prevalence of premenstrual syndrome and higher awareness about syndrome and prevailing treatment options. Asia Pacific and Middle East and Africa together present lucrative opportunities to manufacturers offering PMS treatment drugs. Large pool of females in childbearing age, growing literacy rate and working population significantly contribute to growing opportunities in the region. Growing number of government initiatives and campaigns focusing on women and maternity health are further driving the market growth.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pre-Menstrual Syndrome Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.
  • Geographical revenues generate by countries considered in the report
  • Micro and macro environment factors that are currently influencing the Pre-Menstrual Syndrome Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

ATTRIBUTE DETAILS
Research Period  2022-2032
Base Year 2023
Forecast Period  2024-2032
Historical Year  2022
Unit  USD Million
Segmentation
Drugs Type
  • Analgesics (pain killers)
  • Oral Contraceptive Pills (OCPs)
  • Gonadotropin-releasing Hormone (GnRH)
  • Antidepressants
  • Ovarian Suppressors
  • Diuretics
  • Benzodiazepines

 Region Segment (2022-2032; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Pre-Menstrual Syndrome Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2032.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Pre-Menstrual Syndrome Treatment market?
  • Which is the largest regional market for Pre-Menstrual Syndrome Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Pre-Menstrual Syndrome Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Pre-Menstrual Syndrome Treatment market worldwide?
Choose Licence Type
$4500
$6500
$9000
Why Acute
View Other Reports